MedTrace Logo

Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)

NCT02615938 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-12-03

Study results available
· View outcomes & findings →

Summary

This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.

Conditions

Interventions

DRUG

Hydroxychloroquine sulfate

Apply drug to modify lysosomal pH

OTHER

Placebo

Apply Placebo not to modify lysosomal pH

Sponsors & Collaborators

  • Matthias Griese

    lead OTHER

Principal Investigators

  • Matthias Griese · Hauner Children´s Hospital, LMU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Weeks
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-21
Primary Completion
2019-06-27
Completion
2020-09-09

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02615938 on ClinicalTrials.gov